MT 3995

Drug Profile

MT 3995

Alternative Names: MT-3995

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Class Antihyperglycaemics; Antihypertensives
  • Mechanism of Action Aldosterone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic nephropathies; Non-alcoholic steatohepatitis
  • Discontinued Hypertension

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Diabetic-nephropathies in USA (PO, Capsule)
  • 26 Sep 2017 Mitsubishi Tanabe Pharma completes a phase II extension trial for Diabetic nephropathy in Japan (NCT02676401)
  • 01 Jan 2017 Mitsubishi Tanabe Pharma Corporation completes a phase II trial for Diabetic nephropathies in Japan (NCT02517320)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top